LB-4330

N/A

Report date: 2026/01/21 20:00:47

Base Information

Drug NameLB-4330
Drug Alias NameLB-4330Bis-2
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CLDN18CD8-positive T-Lymphocytes stimulants
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsSolid tumoursUterine Cervical Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesL&L Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesL&L Biopharma (Ningbo) Co LtdL&L Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A